Zacks: Analysts Expect Edwards Lifesciences Co. (NYSE:EW) to Announce $0.64 Earnings Per Share

Equities analysts expect that Edwards Lifesciences Co. (NYSE:EWGet Rating) will post earnings per share of $0.64 for the current quarter, Zacks Investment Research reports. Ten analysts have made estimates for Edwards Lifesciences’ earnings, with estimates ranging from $0.63 to $0.65. Edwards Lifesciences also reported earnings of $0.64 per share during the same quarter last year. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Edwards Lifesciences will report full year earnings of $2.56 per share for the current financial year, with EPS estimates ranging from $2.53 to $2.60. For the next year, analysts anticipate that the business will post earnings of $2.83 per share, with EPS estimates ranging from $2.75 to $2.95. Zacks’ EPS calculations are an average based on a survey of research firms that cover Edwards Lifesciences.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its quarterly earnings data on Tuesday, April 26th. The medical research company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.58 by $0.02. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the previous year, the firm posted $0.54 earnings per share. Edwards Lifesciences’s quarterly revenue was up 10.2% on a year-over-year basis.

Several research firms recently commented on EW. Canaccord Genuity Group dropped their price objective on shares of Edwards Lifesciences from $152.00 to $137.00 in a research note on Wednesday, April 27th. Zacks Investment Research raised shares of Edwards Lifesciences from a “sell” rating to a “hold” rating and set a $115.00 price objective on the stock in a research note on Friday, April 29th. Wolfe Research started coverage on shares of Edwards Lifesciences in a research note on Tuesday, April 5th. They set an “outperform” rating and a $134.00 price objective on the stock. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $130.00 to $122.00 and set an “outperform” rating for the company in a report on Thursday, January 27th. Finally, SVB Leerink decreased their target price on shares of Edwards Lifesciences from $135.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 21st. Five analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Buy” and a consensus price target of $127.50.

NYSE:EW traded down $0.05 during mid-day trading on Friday, hitting $94.32. 2,956,679 shares of the company’s stock were exchanged, compared to its average volume of 3,255,345. Edwards Lifesciences has a one year low of $91.52 and a one year high of $131.73. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.41 and a quick ratio of 2.64. The business has a fifty day moving average price of $111.18 and a 200 day moving average price of $113.79. The company has a market cap of $58.64 billion, a PE ratio of 38.66, a P/E/G ratio of 2.85 and a beta of 1.16.

In related news, Director Martha H. Marsh sold 28,722 shares of the firm’s stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $108.09, for a total value of $3,104,560.98. Following the transaction, the director now directly owns 26,777 shares of the company’s stock, valued at approximately $2,894,325.93. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,550 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $94.82, for a total value of $3,086,391.00. Following the completion of the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $14,920,211.46. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 230,031 shares of company stock worth $24,846,994. Company insiders own 1.29% of the company’s stock.

A number of institutional investors have recently made changes to their positions in EW. EverSource Wealth Advisors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $29,000. American National Bank raised its holdings in Edwards Lifesciences by 99.1% during the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the period. Core Alternative Capital raised its holdings in Edwards Lifesciences by 513.2% during the first quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 195 shares during the period. Northwest Investment Counselors LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $30,000. Finally, Rinkey Investments bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $29,000. 82.54% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.